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Applications of ‘hot’ and ‘cold’ 
bis(thiosemicarbazonato) metal 
complexes in multimodal imaging 
 
Fernando Cortezon-Tamarit, Sophia Sarpaki, David G. 
Calatayud, Vincenzo Mirabello and Sofia I. Pascu* 
 
ABSTRACT: The applications of coordination chemistry to molecular imaging has 
become a matter of intense research over the past 10 years. In particular, the applications 
of bis(thiosemicarbazonato) metal complexes in molecular imaging have mainly been 
focused on compounds with aliphatic backbones due to the in vivo imaging success of 
hypoxic tumors with PET (Positron Emission Tomography) using 64CuATSM [copper 
(diacetyl-bis(N4-methylthiosemicarbazone))]. This compound entered clinical trials in US 
and UK during the first decade of the 21st century for imaging hypoxia in head and neck 
tumors. The replacement of the ligand backbone to aromatic groups, coupled with the 
exocyclic N’s functionalization during the synthesis of bis(thiosemicarbazones) opens the 
possibility to use the corresponding metal complexes as multimodal imaging agents of use 
both in in vitro for optical detection, and in vivo when radiolabeled with several different 
metallic species. The greater kinetic stability of acenaphthenequinone 
bis(thiosemicarbazonato) metal complexes with respect to that of the corresponding 
aliphatic ATSM complexes allowed the stabilization of a number of imaging probes, with 
especial interest in ‘cold’ and ‘hot’ Cu(II) and Ga(III) derivatives for PET applications and 
111In(III) derivatives for SPECT (Single-Photon Emission Computed Tomography) 
applications, whilst Zn(II) derivatives display optical imaging properties in cells, with 
enhanced fluorescence emission and lifetime with respect to the free ligands. Preliminary 
studies have shown that gallium-based acenaphthenequinone bis(thiosemicarbazonato) 
complexes are also hypoxia selective in vitro, thus increasing the interest in them as new 
generation imaging agents for in vitro and in vivo applications. 
 
Introduction 
There has been some significant interest in the use of nitrogen/ 
sulfur/oxygen (N/S/O) donors to generate metal complexes with 
high kinetic stability in aqueous environments.[1–4] The 
thiosemicarbazonato motif has been known since the early 1900 
and bis(thiosemicarbazones) (BTSC) were described as a way to 
functionalize and isolate diketones.[5] However, their study was 
systematized and their properties as metal chelators understood 
only from the 1950s.[6] The great interest in these compounds and 
their metal complexes was mainly motivated by their biological 
activity. They are known to have properties as antibacterial,[7],[8] 
antifungal,[9],[10] antiviral,[11] or antineoplastic[12],[13]. Through the 
pioneering work of Fujibayashi,[14],[15] Blower,[16] Lewis[15],[17] and 
Dilworth[18] there has also been a great interest in the application 
of bis(thiosemicarbazonato) metal complexes as molecular 
imaging agents, especially due to the hypoxia selectivity of some 
of these derivatives. CuATSM has certainly been the most studied 
bis(thiosemicarbazonato) metal complex so far. It has 
demonstrated its efficacy as an imaging probe to delineate 
hypoxia in tumors and cardiac ischemia.[14,19–21] It was first used 
in clinical trials in 2000[22] and further clinical studies had provided 
useful information in patients with lung,[22],[23] cervical[21],[24] and 
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Figure 1 Examples of ATSM complexes studied by fluorescence microscopy in vitro; 1, substitution with 
stilbene, 2, attached of a BODIPY fluorophore, 3, tag with pyrene. 
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rectal[25] cancers. A number of reviews about thiosemicarbazones 
have appeared in the literature over the recent years. The first 
example, reported by Livingstone et al.,[26] included 
thiosemicarbazones as part of a broader work in N/S donor 
ligands. In subsequent cases, the works have been centered on 
the thiosemicarbazide and thiosemicarbazone ligands, looking 
mainly at the coordination chemistry[27] with an exhaustive 
overview by Lobana et al. in 2009.[28] Specific reviews applied to 
the role of bis(thiosemicarbazonato) complexes in imaging had 
also appeared in the recent literature[29] along with structural 
studies and application of copper(II) derivatives as drugs[30] and 
radiopharmaceuticals.[31]  
 
As mentioned above, the main current applications of 
bis(thiosemicarbazonato) complexes have been focused on PET 
with 64Cu. However, in this context, other metals as zinc(II), 
gallium(III) or indium(III) have also been explored.[3] The 
broadening of the scope of metals, along with the substitution of 
the thiosemicarbazide and the change in the backbone has 
provided fluorescent bis(thiosemicarbazonato) complexes and 
allowed their use in multimodal imaging, i.e. as imaging agents in 
more than one technique.[32] Bis(thiosemicarbazonato) 
complexes have so far been used in pre-clinical research of 
reference to PET, SPECT and confocal microscopy. [1],[2],[4] 
 
The aim of this review is to provide a personal account of the 
general background on the use of bis(thiosemicarbazonato) metal 
complexes in molecular imaging, which is central to our recent 
work, with a particular emphasis on their role in recent advances 
in molecular imaging. Over the past decade, we have sustained 
work forwards a long-lasting interest in understanding the 
structure-function relationships underlining the potential of 
bis(thiosemicarbazonato) metal complexes for applications in 
multimodal imaging involving PET/SPECT/optical modalities. The 
molecular design and the selectivity of this class of compounds 
for the evaluation of hypoxia will be highlighted herein. 
Synthesis 
Synthesis of ligands 
 
To date, the synthesis of bis(thiosemicarbazone) ligands has 
been mainly carried out by functionalization of a 1,2-diketone with 
a thiosemicarbazide forming the iminic bond (Scheme 1, 2) by 
heating both components in an alcoholic solution in the presence 
of an acid catalyst.[33] The syntheses are generally successful and 
proceed in good yields, but alongside the desired reaction 
pathways, a number of side reactions leading to cyclization 
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Scheme 1 Different synthetic routes to aliphatic bis(thiosemicarbazones)  
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products or dimers have also been observed to occur (Figure 1, 
A, C).[34],[35] 
 
Several other synthetic strategies were developed over the last 
decades to achieve thiosemicarbazones as using hydrazones, 
oximes or dithiocarbazides as precursors.[33] In 2006 a 
compendium of the available methods of synthesis and potential 
problems in the synthesis of bis(thiosemicarbazones) as ligands 
for molecular imaging was reported by Dilworth et al.[35] The 
majority of bis(thiosemicarbazones) reported in the literature are 
derived from 1,2-diketones. However, the use of 1,3-,[36] 1,4-[36],[37] 
or 1,5-[38] diones have been reported. The most studied 
precursors are perhaps 2,3-butanedione, pyruvaldehyde and 
glyoxal which were found to lead to the formation of most of the 
members in the family ATSM ligands and their complexes. 
 
The synthesis of symmetrical bis(thiosemicarbazones) is 
generally less challenging. However, successful examples of 
unsymmetrical BTSC ligand derivatives can also be obtained.[35] 
Unsymmetrical vicinal dicarbonyl compounds can be used as 
precursors of the reaction. However, they can easily lead to 
mixtures of components that are complicated to purify.[39]  
 
A stepwise condensation of a 1,2-dicarbonyl compound with two 
different thiosemicarbazides is the most exploited strategy 
although it was reported that the reaction conditions need to be 
controlled carefully, as even small variations in time or 
temperature can result in disproportionation of the product giving 
a statistical mixture of products.[35],[40]  
 
This behavior could be attributed to the reversible character of the 
imine-enamine bond[41] coupled with the capability of thiol groups 
to undergo, in the presence of O2, an exchange process leading 
to the formation of disulfide S-S bonds. These features specific to 
thiosemicarbazones might result in a dynamic correlated 
exchange leading to complex mixtures under thermodynamic 
control. The production of dynamic combinatorial libraries 
involving the thiol-disulfide exchange, imines and hydrazones 
have been well studied[42] and our current experimental 
observations point towards the fact that a similar reactivity is likely 
to occur for the bis(thiosemicarbazone) species studied recently. 
The dynamic combinatorial exchanges are influenced by the 
variable pH, water/air presence and solvents such as DMSO: all 
these conditions can affect the synthesis of all mono- and 
bis(thiosemicarbazones) and the behavior of the resulting metal 
complexes species en route for imaging applications. 
 
Coordination Chemistry 
Thiosemicarbazones are incredibly versatile ligands. In solution 
phase, they have been found in a tautomeric equilibrium between 
Table 1. Metals reported to form thiosemicarbazones complexes, by 
Group in Periodic Table[28] 
5 6 7 8 9 10 11 12 13 14 15 
        Al   
V Cr Mn Fe Co Ni Cu Zn Ga   
 Mo Tc Ru Rh Pd Ag Cd In Sn  
 W Re   Pt Au Hg Tl Pb Bi 
U           
Scheme 2 Tautomeric equilibrium in thiosemicarbazones 
Figure 2 Common coordination modes of mono and bis(thiosemicarbazone) 
ligands to the metal 
Figure 1 Molecular structures of A) bicyclic subproduct observed during the 
synthesis of aliphatic bis(thiosemicarbazones[34]; B) bis(4-allyl-3-
thiosemicarbazone) acenaphthenequinone ligand; C) bis(4-ethyl-3-
thiosemicarbazone) acenaphthenequinone derivative presenting a disulfide 
bridge[1] 
A B 
C 
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the thione and thiol forms (Scheme 2). Therefore, they can bind 
to the metal in neutral form as a thiol or anionic form through the 
iminic nitrogen and sulfur atom when the thiol proton is lost. 
 
These ligands provide an anionic S2- ligand ready to bind to the 
metal without the tendency of thiolate to form disulfide bridges in 
the presence of metal atoms.[43] They have been known to act as 
chelators of a wide variety of metals including transition metals, 
main group metals or semimetals as seen in Table 1. A large 
number of examples can be found in the reviews mentioned in the 
introduction.[27–29] 
 
The corresponding 3d metal complexes are usually obtained by 
refluxing the ligand and the metal acetate, halide, sulfate, etc., 
although the reaction can also be carried out under room 
temperature conditions.[28] 
 
The binding of mono(thiosemicarbazones) occurs normally 
through the N/S atoms acting as bidentate ligands. However, they 
can also act as tridentate ligands if any of the substituents has a 
donor atom and it is involved in the coordination to the metal 
(Figure 2, II). Other, coordination possibilities have been 
described, as monodentate through the S atom or bidentate and 
tridentate with the S atom bridging different metals but these 
examples will not be discussed here. Bis(thiosemicarbazones) 
can also bind in neutral and anionic form by the N and S atoms 
through both arms acting as tetradentate ligands. The resulting 
complexes have usually the form of III or IV in Figure 2. The latter 
includes the participation of a donor atom in the backbone group 
between the imine moieties in the coordination to the metal.  
 
In this work, the overview of the coordination chemistry is mainly 
focused on tetradentate bis(thiosemicarbazones) chelating the 
metals of interest in imaging and their precursors (i.e. Zn(II), 
Cu(II), Ga(III), and In(III)). 
 
The analysis of the X-ray structures for a family of 
acenaphthenequinone bis(4-methyl-3-thiosemicarbazonato) 
metal complexes is reported in the following sections. Molecular 
parameters such as bond distances, angles and the resulting 
geometries of novel zinc(II), copper(II), nickel(II), gallium(III) and 
indium(III) complexes are discussed (vide infra). 
Multimodal imaging 
The use of different imaging techniques in order to have better 
visualization of a pathogenic condition either in vitro and/or in vivo 
became an established field over the past 10 years. PET, SPECT 
and confocal fluorescence are the main biomedical imaging 
techniques widely used for imaging tumours either in vivo or in 
vitro. The first two are based on emission tomography (ET) 
principles. ET utilizes radioactive elements (radiotracers) to 
permit the visualization of the body’s anatomy and can depict the 
spatial distribution of different physiological processes such as 
glucose metabolism thus facilitating the detection of the relevant 
diseases (tumors, etc.).[44] However, they are distinguishable 
because of the type of the radioisotope each one uses. As 
indicated by their names, PET’s isotopes of choice are positron 
emitters, whereas SPECT uses single photon emitters. The third 
method mentioned above is an imaging technique which uses the 
excitation states of fluorescent molecules to image specific 
biological systems. All three techniques could potentially be used 
in combination resulting in better images of the same target. The 
combination of PET and MRI has also generated a great interest 
over the last few years. This topic, however, will not be discussed 
herein as it has made the topic of several different reviews and 
reference books.[45-47] 
 
The use of bis(thiosemicarbazonato) metal complexes has been 
normally limited to PET with 64Cu or 68Ga aliphatic complexes. 
Some research has been conducted on the dual labelling of 
ATSM ligands with 64Cu and other radionuclides as 123I[48] or 18F[49] 
in an attempt to understand the biological fate of copper in vivo 
and clarify the mechanism of hypoxia selectivity. In addition to the 
dual labelling of bis(thiosemicarbazonato) metal complexes to 
Figure 3 Structures of peptide-functionalized copper complexes of 
bis(thiosemicarbazones) 
Figure 4 Structures of ATSM complexes incorporating aliphatic backbones 
studied by fluorescence microscopy (top) and fluorescence lifetime maps and 
sample point decay curves of a CuATSM-BODIPY complex in HeLa cells after 
20 min incubation (bottom). Adapted from Ref. [4] with permission from The 
Royal Society of Chemistry 
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study their use as multimodal imaging agents, the derivatization 
with biologically active molecules has also been explored. 
Dilworth et al. prepared a copper complex with one of the ligands 
including a carboxyphenyl thiosemicarbazide. The carboxylic acid 
functionality was used to attach different peptides including 
octreotide, a somatostatin analog with improved pharmacological 
properties (Figure 3).[50],[51] However, the first in vitro and in vivo 
study of a functionalized bis(thiosemicarbazone) involved the 
functionalization of a thiosemicarbazide with an aromatic group 
bearing different functionalities as hydroxyl, nitro or even a 
nitroimidazol moiety. Some of the examples proved to be hypoxia 
selective in vitro and in vivo although with a high liver uptake, 
pointing out to the necessity of opening new directions into the 
field of functionalization of these compounds, to bypass 
limitations in liver biodistribution.[52] A similar strategy was used 
by Donnelly et al. to synthesize a copper bis(thiosemicarbazone) 
complex with bombesin, a targeting peptide towards receptors 
overexpressed in prostate cancer cells. In this case, the 
radiolabelling with 64Cu is reported but not in vitro or in vivo 
studies were carried out.[53] The same group explored the 
preparation of copper radiopharmaceuticals using bombesin as a 
target but changing the chelating system to macrobicyclic 
cages.[54] 
 
Dilworth et al. continued the study of bifunctional chelators by 
functionalization of a NH2 tagged CuATSM variant with aliphatic 
and aromatic carboxylate linkers.[55] The prepared derivatives 
were coupled to biomolecules, namely biotin and bombesin, the 
latter by reacting the metallic complex with the peptide during the 
solid phase synthesis. The compounds were radiolabeled at room 
temperature with 64Cu and 99mTc showing applicability to PET and 
SPECT studies. Furthermore, the in vitro binding to PC-3 cells 
and in vivo localization in mice was evaluated. 
 
The study of aliphatic bis(thiosemicarbazonato) metal complexes 
using optical techniques has been difficult due to the lack of 
fluorescence of the complex or the thiosemicarbazone 
substituents. Despite these difficulties, ATSM-like 
bis(thiosemicarbazone) complexes had been used to monitor the 
in vitro uptake of its metal adducts by fluorescence imaging. 
Dilworth et al. discovered a fluorescent ZnATSM derivative with 
modified side chains and studied the uptake in different cell lines 
by fluorescence microscopy. This work proved that the uptake of 
the complex was strongly cell line dependent.[56] Previous studies 
also established that fluorescence was driven by an intraligand 
excitation.[57] However, the fluorescence intensity of the 
aforementioned derivatives was weak. 
 
In fact, excluding the latter example, no fluorescence microscopy 
study of the behavior of these compounds in vitro was possible 
unless a fluorophore was attached to the 
bis(thiosemicarbazonato) core thus modifying their original 
properties.  
 
Groups acting as a fluorophore have been attached to ATSM-like 
complexes in order to study their properties in cells (Figure 4). 
The use of pyrene with Cu(II) and Zn(II) complexes has been 
evaluated and the uptake in HeLa cells investigated. Pyrene is 
known to act as DNA intercalator.[58] Therefore, such planar 
system, was deliberately selected in this work in order to prepare 
a hypoxia selective compound that targeted nuclear DNA. 
However, the complexes did not present nuclear uptake and their 
uptake was not enhanced under hypoxia.[59] A similar approach 
was followed by Donnelly et al. with a different purpose. In the 
same manner as cited above, they appended a stilbene group to 
one of the arms of a Cu(II) complex that, excluding this group, had 
the structure of CuATSM. The stilbene group provides a target to 
amyloid-β plaques deposited in the brain tissue under Alzheimer 
or dementia diseases.[60] The stilbene functionality also kept its 
original fluorescence when the complex was formed despite the 
presence of Cu(II). Therefore, its interaction with amyloid-β 
plaques in human brain sections was studied by epi-fluorescence 
microscopy.[61] Recently, examples of fluorescent 
thiosemicarbazonato complexes derived from pyrene and 
anthracene have also been prepared and tested in vitro.[62],[63] 
However, in both cases, the thiosemicarbazone acted as a 
bidentate ligand. The copper complexes derived from the 
anthracene ligand were studied as chemoterapeutic agents for 
cervical cancer[62] while the rhodium and iridium pyrene 
derivatized half-sandwich complexes were found to interact with 
DNA and presented some interest against lung and breast cancer 
cell lines[63]. 
 
As mentioned above, the possibility of tagging the ATSM core with 
a chromophore suitable for fluorescence in vitro had drawn the 
attention of several research groups over the last years. Dilworth, 
Pascu and collaborators reported a novel approach to evaluate 
the stability of bis(thiosemicarbazonato) complexes in vitro.[4] This 
objective was achieved by linking a BODIPY fluorophore to the 
CuATSM core. BODIPYs are known to be bright fluorophores with 
high quantum yields and good stability in biological media.[64] 
Interestingly, this was the first case of application of Fluorescence 
Lifetime Imaging Microscopy (FLIM) coupled to confocal laser 
scanning microscopy to the study of ATSM complexes. The 
results of these experiments are discussed on the following 
sections. 
 
The synthesis of bis(thiosemicarbazones) from an aromatic 
diketone, like acenaphthenequinone, would resolve the problem 
of the attachment of a fluorophore to the complex as the backbone 
would be intrinsically fluorescent. Examples of 
mono(thiosemicarbazones) synthesized from 
acenaphthenequinone have been reported in literature since the 
1950s when the efficacy of thiosemicarbazide derivatives in the 
treatment of tuberculosis was discovered.[65] Other examples 
followed, including the formation of acenaphthenequinone 
mono(thiosemicarbazonato) complexes with several metals 
(Mg(II), Co(II), Ni(II), Cu(II), Zn(II), Cd(II)) involved in 
physicochemical studies[66] and Ru(III) and Pt(IV) for analytical 
purposes.[67] It is worth noting that mono(substituted) ligands 
presented antiproliferation activity. Iron, nickel, copper and zinc 
mono(thiosemicarbazone) adducts were studied by Fava et al. 
These studies suggested that such ligands and selected 
complexes presented inhibition of cell proliferation and DMSO-
induced differentiation.[8] This research can certainly be 
considered an important achievement in the chemistry of 
thiosemicarbazones and its metal adducts by applying a different 
non-aliphatic backbone. However, it did not explore the capability 
of this class of ligands to act as tetradentate ligands and 
performance as fluorescent probes. 
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It was not until 2007 that Pascu et al.[68] reported the first metal 
complexes of Zn(II) and Cu(II) based on an 
acenaphthenequinone bis(thiosemicarbazone) ligands. The 
intrinsic fluorescence of the acenaphthene group in the backbone 
of the metal complex allowed the in vitro study of the uptake in 
different cancer cells. In this case, the zinc(II) complex can be 
obtained in a template process by refluxing 
acenaphthenequinone and an excess of thiosemicarbazide in the 
presence of zinc acetate (Scheme 3, step 1).  
 
It was found that the most efficient strategy to arrive to other metal 
complexes as nickel(II), copper(II), gallium(III) or indium(III) was 
by transmetalation of the zinc(II) derivative (Scheme 3, step 
2).[2],[3] The synthesis of acenaphthenequinone mono and 
bis(thiosemicarbazone) ligands has also been reported. They can 
be obtained via conventional heating refluxing 
acenaphthenequinone with the thiosemicarbazide in ethanol in 
the presence of hydrochloric acid.  
 
However, our recent work reported a new procedure which 
applied microwave radiation to obtain these derivatives: we found 
that the synthesis was faster and superior yields were obtained 
whilst opening up the field of sustainability in the production of 
‘hot’ as well as ‘cold’ molecular imaging agents.[1] 
 
The viability of the zinc(II) bis(4-allyl-3-thiosemicarbazonato) 
complex to carry out PET experiments was assessed by the 
radiolabeling of the cited complex with 64Cu. The reaction 
proceeded in 30 min using 64Cu(OAc)2 and was analyzed by High 
Performance Liquid Chromatography (HPLC) integrated with a 
UV and radioactivity detectors. One of the advantages of the use 
of the transmetalation reaction to obtain the hot complex is that 
the cold zinc(II) complex could be prepared, purified and 
characterized with everyday laboratory facilities.  
 
Further studies explored novel substituents of thiosemicarbazone 
such as exocyclic groups and Zn(II) complexation. The uptake in 
cellular cancer cells was studied as well as the cytotoxicity 
towards some standard cancerous cell lines, that was found to be 
comparable to that of cisplatin.[69] 
 
Furthermore the systematic study of the synthesis and properties 
of bis(thiosemicarbazonato) acenaphthenequinone complexes 
was reported in the paper published by Pascu et al. in 2010. In 
this work, the coordination of zinc(II), nickel(II) and copper(II) with 
ethyl and methyl thiosemicarbazone was investigated.[2] 
In the first two cases, the complexes have been synthesized in a 
one-pot template process. Acenaphthenequinone and an excess 
Scheme 3 Synthesis route to acenaphthenequinone bis(thiosemicarbazonato) complexes. The best way to obtain complexes with metals different than Zn (i.e. Cu, 
Ga, Ni, In) was via transmetalation from the corresponding Zn derivative 
Figure 5 Molecular structures of different bis(4-methyl-3-thiosemicarbazonato) acenaphthenequinone metal complexes. Color codes: S: yellow, N: blue, C: dark 
grey. H: white 
thiosemicarbazonato) acenaphthenequinone metal complexes. 
 
Figure 3 
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of thiosemicarbazide generate the corresponding 
bis(thiosemicarbazone) in the presence of the metal the 
coordination of which acts as a driving force for the reaction. 
However in the case of the copper(II) complex, this strategy failed 
and the complex was only obtained by Zn(II)/Cu(II) 
transmetalation in the presence of Cu(OAc)2 (Scheme 3). The hot 
transmetalated 64Cu derivative was obtained after a 20 min 
reaction. The cold complexes were characterized by single crystal 
X-ray diffraction and EPR, as well as by cyclic voltammetry 
techniques. 
X-ray structures of the complexes were obtained (Figure 5) and a 
coordination equilibrium was observed in addition to the E/Z 
geometric equilibrium present when the substituent of the 
thiosemicarbazone was an allyl group (Scheme 4). 
The geometry formed in the case of copper(II) and nickel(II) is 
square planar. The coordination mode of the ligand leads to the 
formation of three five-member chelate rings that confer high 
stability to the complex. The ligand skeleton can be considered 
planar with a maximum deviation from the least-square plane of 
0.040 Å for Cu and 0.044 Å for the Ni (Figure 5 and Table 2). In 
the case of other metals as zinc(II), galium(III) and indium(III) the 
Figure 6 Confocal microscopy and fluorescence lifetime imaging of metal complexes 1-3 in HeLa cells and 3 in PC-3 cells. All complexes were added in 50 µM 
concentration and imaged after 1 h incubation. a) e) i) m) 1-Photon fluorescence emission – overlay of green and bright field channels (λex 488 nm); b) f) j) n) 2-
photon fluorescence imaging – intensity image (λex 910nm); c) g) k) o) 2-photon fluorescence lifetime imaging map (λex 910 nm) and d) h) l) p) corresponding 
lifetime distribution plot. Scalebar: 20 µm. Adapted from Ref. [3] with permission from The Royal Society of Chemistry. 
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geometry is squared pyramidal with the metal atoms lying around 
0.555 Å outside of the mean plane comprised of atoms C1, N1, 
N2, C2, C3, N3, N4 and C4 (Figure 5 and Table 2). The metal 
atom is coordinated to the dideprotonated tetradentate 
bis(thiosemicarbazone) and one chloride or solvent molecule 
occupies the apex position. For the indium complex, the 
coordination mode of the ligand leads to the formation of three 
five-member chelate rings that confer high stability to the complex 
as for the Cu and Ni complexes. However, for the Ga and Zn 
complexes the ligand coordinates in a tetradentate mode through 
the N1, N3, S1 and S2 atoms, leading to the formation of three,  
four and six member chelate rings, being the dihedral angles N2-
C2-C3 and C2-C3-N3 different (Table 2). Due to this coordination 
mode the square pyramidal geometry of the Zn and Ga 
complexes is more distorted. All the C2–C3, C2–N2 and C3–N3 
bond distances are within the range of other complexes found in 
the literature, which depend on the nature of the metal center, and 
do not deserve further comments. The distances of the bonds 
(Table 2) are in the same range for all complexes, which indicates 
the versatility of the TSC to accommodate different sizes and  
preferences coordinative metal ions, despite the higher rigidity of 
the backbone in comparison with other TSC due to the 
acenaphthenequinone group. 
 
Although 64Cu is a well-known and used metal in PET studies and 
it has been the metal of choice for the study of ATSM, the 
generation process is not optimal for clinical applications as it can 
only be obtained from a cyclotron despite its very favorable half-
life (t1/2) of 12.7 h which allows for transport to remote sites and 
further derivatizations. Due to the availability of generators, the 
research in 68Ga aqueous chemistry has strongly arisen in the 
past decade within the radiochemistry and molecular imaging 
research community, which is now geared towards pre-clinical as 
well as clinical applications of this radionuclide. The generation 
process of 68Ga is more straightforward and affordable for clinical 
application due to the use of a 68Ge/68Ga generator that allows 
obtaining a readily available dose in a shorter time and can be 
done in the clinical facility. Furthermore, 68Ga t1/2 is 68 minutes 
which is in the desired range for an imaging experiment. The 
chemical process where the hot derivative is involved has to be 
rapid enough but timing is not a crucial issue as with 18F which 
has a t1/2 of 109.7 min and significantly more challenging multi-
step radiochemistry in our experience. It also, allows the patient 
to receive a lower radiation dose post injection and after the 
experiment.[70] Considering these advantages and the 
appearance of new radionuclides for clinical uses, the preparation 
of bis(thiosemicarbazonato) acenaphthenequinone complexes of 
gallium(III) and indium(III) was studied.[3] The cold complexes of 
Ga(III) and In(III) with ATSM and acenaphthene backbones were 
synthesized following the described procedures in a template 
process from the Zn complex in the case of acenaphthenequinone 
and from the ligand for ATSM. The side groups included in this 
study were methyl and allyl for the acenaphthenequinone 
derivatives. The optical imaging of the allyl functionalized zinc(II), 
gallium(III) and indium(III) complexes was studied in PC-3 and 
HeLa cells by 1 and 2-photon fluorescence imaging as well as by 
FLIM (Figure 6). The possibility of obtaining 2-photon 
fluorescence lifetime imaging maps allows to ascertain that the 
complexes are intact in the imaging time scale. In addition, the 
radiolabeling experiments were carried out by transmetalation of 
“cold” Zn(II) precursors to “hot” 68Ga and 111In derivatives and 
studied by radio HPLC (Figure 7). Challenges of the complexes 
Table 2 Selected bond distances and angles for the 
bis(thiosemicarbazonato) metal complexes 
 1 2 3 4 5 
C2-C3 (Å) 1.470(6) 1.477(5) 1.495(6) 1.468(12) 1.490(2) 
C2-N2 (Å) 1.307(6) 1.299(3) 1.284(6) 1.370(2) 1.306(19) 
C3-N3 (Å) 1.309(6) 1.299(3) 1.314(6) 1.356(9) 1.320(19) 
N2-C2-C3 (°) 116.2(4) 113.8(15) 134.3(4) 140.1(9) 117.3(15) 
C2-C3-N3 (°) 116.1(4) 113.8(15) 122.0(4) 118.8(8) 117.2(15) 
Distance out 
of plane* of 
the metal (Å) 
-0.040(14) 0.044(10) -0.555(13) -0.545(3) -0.553(5) 
* mean plane comprised of atoms C1, N1, N2, C2, C3, N3, N4 and C4  
 
 
Scheme 4 Coordination equilibrium found in bis(4-allyl-3-thiosemicarbazonato) 
metal complexes 
Figure 7 HPLC traces from different radiolabelling experiments: a) Radio-HPLC trace of the 64Cu labelling for the bis(4-ethyl-3-thiosemicarbazonato) 
acenaphthenequinone complex[2]; b) overlay of UV-HPLC trace for the Zn(II) bis(4-allyl-3-thiosemicarbazonato) acenaphthenequinone precursor and the radio-
HPLC for the 111In labelling[3]; c) overlay of the UV-HPLC and radio-HPLC traces for the 68Ga microwave labelling of the bis(4-allyl-3-thiosemicarbazonato) 
acenaphthenequinone. b) c) Adapted from Ref. [1] with permission from The Royal Society of Chemistry. 
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in water and serum revealed that both ‘cold’ precursors and ‘hot’ 
derivatives of 68GaATSM and 111InATSM have an extremely low 
kinetic stability in aqueous environments compared to 64CuATSM 
and were, therefore, not appropriate for radiolabeling studies thus 
far. 
Imaging of hypoxia 
Hypoxia and Cancer 
In the 1950s, Gray and colleagues first pointed out both the 
presence of low oxygen tensions in human tumors[71] and the 
possibility that radiation results can be influenced by those 
regions.[71],[72] Therefore, research was focused on allowing for an 
increase in the sensitivity of the hypoxic cells by using either 
hyperbaric oxygen chambers[73] (before early 1970s) or small 
molecules mimicking oxygen’s effects[74] (after 1980s). By the 
1990s, it was known that the concentration of oxygen levels varies 
in human tumors.[75] To date, variety of studies have confirmed 
the importance of tumor hypoxia and underlined its detrimental 
role in tumor progression and treatment. Therefore, extensive 
studies have been conducted in order to decipher, limit and trace 
hypoxic conditions pathology. 
In tumors, the neoplastic cells often consume more oxygen than 
they are supplied, resulting in growing low oxygen level tissue 
areas. Neoplastic hypoxia can be caused either by perfusion-
limited oxygen delivery (acute hypoxia) which results from 
structural and functional abnormalities of tumor microvessels; by 
diffusion-limited oxygen delivery (chronic hypoxia) as a result of 
the increased distance between the cell and the blood vessel; or 
from tumor-associated and/or therapy induced anemia leading to 
reduced oxygen capacity in blood (anemic hypoxia).[76],[77] In 
hypoxic cells, protein synthesis is reduced leading to restrained 
proliferation and cell death. On the contrary, diversification of cell 
cycle distribution is observed as a consequence of prolonged 
exposure in hypoxic conditions. Those changes are common 
causes of tumor progression as tumor cells establish mechanisms 
in order to evade the hostile environment generated by hypoxia. 
In addition, hypoxia is highly related to apoptosis of both normal 
and neoplastic cells[77-79] and leads to therapy resistance through 
various pathogenic mechanisms (selection of potentially p-53 
mediated senseless cells[78],[79]; (ii) inadequate exposure to 
anticancer drugs through the aforementioned increase in distance 
between cells and blood vessels (acute hypoxia)[80]; and (iii) via 
the upregulation of drug resistant genes and “encoding 
genes”[81]). Alterations in gene expression with subsequent 
changes in the proteome and/or the genome[78] and cell 
selection[78],[79],[82] are the underlying mechanisms of hypoxia’s 
interference with tumor malignancy. Tumor hypoxia is considered 
as a valuable target for tumor prognosis because of its 
relationship with malignant progression, combined with the 
development of resistance to cancer therapies. As a result, a 
variety of detection techniques have been developed throughout 
the years in order to distinguish hypoxia in tumors. This include 
the identification of low oxygen areas[83],[84] the targeting of 
endogenous markers, such as HIF-1 and CAIX,[84],[85] the 
employment of exogenous hypoxia markers, such as 2-
nitroimidazoles,[86] and the use of non-invasive techniques such 
as PET imaging and MRI.[24],[87],[88] 
Hypoxia inducible factors (HIF) 
Hypoxia inducible factors (HIFs) are a family of transcription 
factors notably sensitive to oxygen gradients, pO2. Such 
transcription factors are capable of activating complex gene 
expression models directed to adapt into low oxygen conditions. 
The HIF family consist of 3 different members (HIF-1, HIF-2 and 
HIF-3), all of them constituted of two subunits (α and β). The alpha 
subunit contains an oxygen dependent degradation domain 
(ODD) resulting from the uniqueness of each gene and is 
responsible for the regulation of the hypoxia inducible behavior 
(Figure 8). The beta subunit is a hydrocarbon nuclear translocator 
domain (ARNT) ubiquitously expressed instead.[89],[90] Tumor 
hypoxia is mainly related with HIF-1α and HIF-2α factors and a 
variety of alteration in gene regulation have been proposed 
(Figure 9). Although they similarly activate the gene transcription 
triggered by hypoxia; HIF-2α is mainly active in conditions of 
prolonged hypoxia, while HIF-1α is active in acute hypoxia.[90],[91] 
Figure 9 Mechanism of targeted genes activation by HIF under normoxia (left) 
and hypoxia (right) 
Figure 8 Effects of hypoxia to the organism regulated by HIF 
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Since 1993, it has been demonstrated that iron chelators could 
induce HIF-1α.[92] Later investigations have evidenced that a 
variety of metal (Zn(II), Cu(II), Ni(II), Co(II)) could mimic this iron’s 
characteristic by stabilizing HIF-1α.[93] This could potentially lead 
to the development of metal chelators which will reduce HIF’s 
expression. 
 
Imaging of Hypoxia with ATSM complexes  
The imaging of hypoxia has been based for a long time in the use 
of nitroimidazole compounds labeled with 18F or 123I, being the 
most used 18FMISO, which in a reductive environment gets 
reduced and trapped in hypoxic cells and tissues.[94]  
 
However, nitroimidazoles present a number of disadvantages for 
their routine use as low lipophilicity, slow pharmacokinetics, low 
tumor-to-muscle ratios or the limited clearance from normoxic 
tissue.[95],[96]  
 
Bis(thiosemicarbazonato) complexes for the imaging of hypoxia 
were first employed by Fujibayashi et al. in 1997 in a rat heart 
ischemic model.[14] The retention of a 62CuATSM derivative was 
found to be around 80% under hypoxic conditions in perfused 
isolated hearts while under normoxic conditions the retention was 
not higher than 20%. The hypoxic selectivity of CuATSM in vitro 
and in vivo was later confirmed by other groups.[15],[16] and related 
to the pO2 in tumors.[97] 
 
Since the appearance of this work, bis(thiosemicarbazonato) 
complexes derived from aliphatic 1,2-dicarbonylic compounds 
have attracted the interest of many research groups worldwide. 
The modification of the backbone and substituents of the 
thiosemicarbazides was rapidly explored (Figure 10) and the 
hypoxic retention in vitro evaluated.[16] The variation on the 
hypoxic selectivity in cells was related mainly to the lipophilicity 
and redox potential. These parameters were tuned in an attempt 
to obtain an optimal response.[98] 
 
The mechanism of action of CuATSM as hypoxia tracer has been 
largely debated together with its behavior as a copper transporter 
in vitro and in vivo. The first proposed mechanism of action of 
copper BTSC relies on the fact that the complex crosses the 
membrane due to its high lipophilicity and gets trapped in the cell 
under hypoxic condition with the resulting reduction of Cu(II) to 
Cu(I).[14] This mechanism was further elaborated by suggesting 
that CuATSM is reduced in all cellular environments, not only 
under hypoxia, resulting in a Cu(II)ATSM and Cu(I)ATSM- 
equilibrium. However, in the absence of oxygen, the unstable 
Cu(I)ATSM- complex cannot be reoxidized to the stable Cu(II) 
species and will protonate and dissociate in the presence of 
copper (Figure 11).[18],[99] Density Functional Theory (DFT) 
studies, electrochemical measurements and UV-vis spectra have 
supported this hypothesis. 
 
In an attempt to elucidate the location of the intracellular 
reduction, Fujibayashi et al. analyzed by HPLC lysed Ehrlich 
tumor cells.[100] The reduction process was found to happen 
mainly in the microsome/cytosol instead than the mitochondria, to 
be heat sensitive and enhanced by the addition of NADPH, fact 
that points to an enzymatic reduction of CuATSM.  
 
The mechanism of cellular stability and related decomposition 
pathways of Cu(II) bis(thiosemicarbazones) has also been 
investigated by using DFT calculations.[101],[102] In these work it 
was revealed that the HOMO-LUMO gap of the complex was 
surprisingly small (in the order of 0.05 eV) compared to other 
transition metal complexes and dependent on the substituents. 
The importance of the methyl groups in the ATSM backbone was 
also demonstrated. Derivatives without these groups would 
undergo protonation and degradation intracellularly hence not 
being hypoxic selective.[99],[102]  
 
Furthermore, the characteristics of the series in Figure 10 were 
explored and compared by UV-vis spectroscopy, cyclic 
voltammetry and DFT (looking at structures, vibrations, 
protonation and reduction). These results suggested an 
Figure 11 Proposed uptake mechanism of CuATSM in a cellular environment 
under hypoxia 
Figure 10 Structures of copper bis(thiosemicarbazonato) complexes studied 
during the investigation of the properties and its mechanism of hypoxia 
selectivity 
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irreversible reduction of CuPTSM and CuPTS (where PTS is 
pyruvaldehyde bis(thiosemicarbazone) in the presence of an acid. 
However, UV-vis and Cyclic Voltammetry (CV) studies proved 
that CuATSM undergoes a reversible one electron reduction. 
Despite the approximations made during the calculations, DFT 
works permitted to extract trends between the redox potential of 
the complexes, the LUMO energy and the alkyl groups present in 
the backbone. Such calculations proposed that the HOMO does 
not vary through the series while the LUMO varied from CuATSM, 
where it is metal based generating a singlet state in reduced 
species to CuPTS, where it is ligand based originating a triplet 
state.[103] It was demonstrated that both compounds were reduced 
in the conditions found in vitro. However, CuPTS was reduced 
more efficiently than CuATSM. CuPTS is effectively trapped into 
the cell as, protonated and dissociated, releases Cu(I) cations 
capable to bind intracellular proteins. Under the same 
circumstances, CuATSM can be reoxidized and the original Cu(II) 
species can escape from the cell by diffusion. 
 
The one-electron reduction potentials and absolute pKa values for 
a list of complexes, depicted in Figure 10, were also studied by 
DFT. The low values obtained for the pKa of all complexes 
demonstrated that the protonation in the pH of normal tissue is 
avoided and the complexes can cross cellular membranes. Also, 
electron donating groups at R1 and R2, as NH2, tend to 
destabilize the complex by increasing the energy of the LUMO. 
The cationic species Cu(I)ATSMH2+ was proposed as the initial 
compound trapped in hypoxic cells.[101] 
 
However, the results of a retention study of 64CuATSM in different 
cell lines showed contradictory results that did not follow 
completely the above mentioned mechanism. Therefore, it was 
proposed that 64Cu was not only bound to the ATSM ligand but 
after dissociation, the copper was added into the intracellular pool. 
For this reason, radioactive copper would join the intricate copper 
metabolism where Cu(I) would be protected from reoxidation and 
be transported out of the cell by an active mechanism.[104] 
The difference in retention in the different cell lines tested was 
attributed to the presence and abundance of specific Cu(I) 
transporters. Measured cellular levels can be equivalent to the 
active transport of 64Cu rather than the uptake of CuATSM so the 
results should be taken with caution. 
 
There have also been inconsistencies in prostate cancer models. 
Lewis et al. observed that the retention of 64CuATSM under 
hypoxia in different prostate cancer cell lines was significantly 
lower when compared to other cancer cell lines.[105] It was 
attributed to a defense mechanism where the redox equilibrium of 
the cell is altered and intracellular reductants as NADPH are 
consumed by the over expression of the Fatty Acid Synthase 
(FAS) hence making difficult the reduction of Cu(II) to Cu(I). This 
was demonstrated by blocking the FAS that produced the 
expected increase in retention of 64CuATSM in vitro in four 
different prostate cancer cell lines.  
Figure 13. [68Ga](bis(4-allyl-3-thiosemicarbazonato) acenaphtenequinone 
uptake in EMT6 cells under hypoxic (white bars) or normoxic conditions (black 
bars). Hypoxia in cells was induced for 20 min prior to addition of the tracer in 
1% O2 and cells were maintained under the same conditions for the remainder 
of the time course. Reproduced from Ref. [1] with permission from The Royal 
Society of Chemistry. 
A B 
Figure 12 A Graph showing the radioactivity retention in vitro of 64CuATSM and 64Cu(OAc)2 at 30 min after incubation in HT1080, EMT6 and CaNT cell lines. (CaNT 
cells were excised from in vivo tumors as they cannot be cultured in vitro); B. Graph showing the correlation coefficients accounting for the spatial correlation 
between autoradiography and EF5 immunofluorescence of tumors excised at different times after the administration of 18FMISO, 64CuATSM and 64Cu(OAc)2. (This 
research was originally published in JNM. R. Hueting, et al. A Comparison of the Behavior of 64Cu-Acetate and 64Cu-ATSM in vitro and in vivo. J. Nucl. Med. 2014, 
55, 128-134. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.) 
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The latest contributions to the understanding of the fate of 
bis(thiosemicarbazonato) complexes in vitro and in vivo were 
made by Dilworth et al. in 2013 and 2014. In the first work,[4] GTS 
(glyoxal bis(4-ethyl-3-thiosemicarbazone)) and ATSM metal 
complexes were synthesized with a BODIPY fluorophore 
attached to them in order to overcome the quenching of the 
fluorescence in the paramagnetic copper(II) complexes and 
enhance it in the rest. The lifetime of the complexes was studied 
to evaluate their stability and speciation in vitro. The integrity of 
different BODIPY-tagged ATSM-like complexes in PC-3 and 
HeLa cells was evaluated by FLIM. The poor fluorescence of the 
ligands was used as an indicator of the presence of intact complex 
in cells by confocal microscopy. Furthermore, the stability of the 
metal complexes in vitro was assessed by acquiring lifetime 
imaging maps and decay curves (Figure 4, bottom) under 2-
photon excitation. Then, the lifetime was calculated in HeLa cells 
and in aerobic conditions for times up to 1 h by FLIM coupled to 
confocal laser scanning microscopy (Figure 4, bottom). The data 
confirmed that the copper(II) and nickel(II) BODIPY-tagged 
ATSM-like complexes remain unchanged in cells for times up to 
1 h while the zinc(II) derivative did not provide conclusive data. 
When compared to the latter species, the copper(II) BODIPY-
tagged derivative without the methyl groups in the backbone was 
found to be completely dissociated in 20 min. 
 
The second work[106] compared the behavior of 64Cu(OAc)2 and 
64CuATSM in vivo. While 64Cu(OAc)2 was assumed to be used as 
a control as it showed minimal uptake in EMT6 cells in previous 
works,[52] it was found that the biodistribution was surprisingly 
similar as when 64CuATSM was used. The autoradiography of 
tumors compared to EF5 inmunohistochemical staining revealed 
that there was no spatial correlation for 64Cu(OAc)2 or 64CuATSM 
under hypoxia after 15 minutes or 2 h in contrast to 18FMISO. 
However, the correlation improved at longer times for 64CuATSM 
but also for 64Cu(OAc)2 (Figure 12). These data suggest that a 
proportion of radiocopper, in the ATSM case, is 64Cu bound to 
proteins and not intact complex revealing that copper metabolism 
is being tracked. The hypoxia selectivity seems to be determined 
by the cellular processing of copper that is released from the 
thiosemicarbazone via a redox process. This process is 
necessary to obtain free copper in cells but does not control the 
selective uptake. Ultimately, the data suggests that the 
relationship between CuATSM and hypoxia is not entirely direct 
in vivo compared to in vitro.  
 
Figure 14 In vivo imaging experiments with metal acetates and corresponding complexes of bis(thiosemicarbazones). (A) 68Ga acetate only 60 min post injecion[113]; 
(B) Images of 64Cu acetate, 64CuATSM and 64CuGTSM 30 min post injection. It can be seen how copper acetate shows a similar biodistribution to CuATSM with 
rapid liver uptake. CuGTSM shows uptake not only in the liver and gut but also in the brain and the myocardium [113]; C) MicroPET images of [68Ga]bis(4-ethyl-3-
thiosemicarbazonato) acenaphthenequinone complex in nude mice at different time points.[1] A) B) Reproduced from Ref. [113] with permission from The Royal 
Society of Chemistry; C) Reproduced from Ref. [1] with permission from The Royal Society of Chemistry 
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The application of bis(thiosemicarbazonato) complexes has not 
been limited just to the imaging of hypoxic regions in tumors, it 
has also been used in the imaging of ischemic and hypoxic 
myocardium.[94],[107] In this field, the modification of the complex to 
be more sensitive towards cardiac hypoxia has recently been 
explored.[108]  
 
Copper bis(thiosemicarbazones) based on aliphatic cores have 
proved very useful in delimiting hypoxia areas in tumors and 
myocardium. The functionalization with targeting molecules is 
possible and does not seem to alter greatly the hypoxic selectivity 
providing opportunity to obtain targeted delivery and therapy 
probes. The use of 64CuATSM in therapy has revealed to provide 
improved cytotoxicity and DNA damage under hypoxia.[109] 
However, as some results have highlighted CuATSM undergoes 
a complex uptake mechanism in vitro and in vivo and its 
application for the imaging of tumors seems to be not universal. 
Regarding the therapeutic applications, the optimization of the 
common 64CuATSM needs to be undertaken. Therefore, care 
should be taken in its application and study of the results. 
 
Interestingly, the nature of the bis(4-allyl-3-thiosemicarbazone) 
acenaphthenequinone gallium(III) complex was studied as further 
assays revealed that it shows hypoxic selective behavior under 
the conditions tested in a range of cells. In this work, the improved 
synthesis of mono and bis(thiosemicarbazone) ligands and hot 
complexes was investigated using microwave synthesis. In the 
case of the ligands, the yields were comparable to the ones 
obtained by conventional for the mono(thiosemicarbazones) and 
improved in the case of the bis(thiosemicarbazones). 
Furthermore, the reaction time was reduced from 2 h to under 10 
min. In the case of the hot complexes, the microwave synthesis 
helped in reducing the reaction time, a crucial factor when using 
radionuclides.[1] 
 
Based on the proposed mechanism of hypoxia selectivity 
described above, the redox potentials of the metal complexes 
must be within a very specific range. According to this 
mechanism, the behavior of CuATSM is believed to be ruled by 
the redox chemistry that favors the release of copper in vitro but 
does not regulate the uptake. However, in the case of gallium, no 
redox chemistry is possible under biological conditions so no 
hypoxic behavior was expected. Surprisingly, the [68Ga]bis(4-allyl-
3-thiosemicarbazonato) acenaphthenequinone complex was 
hypoxia selective as evaluated by using flow cytometry and 
radioactive cell count (Figure 13). The electrochemistry of the 
gallium complex and similar non-copper derivatives was studied 
to evaluate if there was an influence of the backbone but no 
reduction or oxidation waves were observed. The proposed 
hypothesis is that gallium(III), which shares certain characteristics 
with iron(III) as charge or size, an ionic radius of 62 pm compared 
to 55 pm in iron(III)[110], is released intracellularly and then trapped 
by one of the potent iron chelators present in the cells. So, in this 
case the hypoxic behavior could be attributed to the track in 
changes in the iron metabolism under hypoxia which is known to 
be altered.[111],[112] 
Preliminary in vivo studies had also been conducted in mice with 
a 68Ga-labeled bis(4-ethyl-3-thiosemicarbazonato) 
acenaphthenequinone complex (Figure 14). The results revealed 
that the compound accumulated in the liver after injection to be 
distributed over the the body of the mouse with time. A 
concentration in the lungs could be observed 2 and 4 h post 
injection. 
Conclusions 
Bis(thiosemicarbazone) ligands and their metallic complexes 
have been extensively investigated over the last 50 years due to 
their pharmacological activity and potential in cancer theranostics 
applications. The family of CuATSM have perhaps been the most 
effective class of bis(thiosemicarbazonato) metal complexes in 
the field of imaging diagnostics in hypoxic tumors. CuATSM 
provided a brand new class of compounds that allowed to 
delineate the origin and extent of hypoxia in tumors and heart 
diseases. The mechanism by which CuATSM-like complexes are 
hypoxia selective involves intricate intracellular reduction-
oxidation events leading to an abundance of Cu(I) species. 
Indeed, in hypoxic environments, these redox equilibria favor the 
formation of Cu(I) containing species and their consequent 
dissociation in a biological environment. A variety of transition 
metals (Zn(II), Ga(III), In(III), Ni(II)) were also investigated 
providing important results that elucidated the fate of such redox 
related processes in cells under hypoxic regime. 
 
The applicability of bis(thiosemicarbazones) as multimodal 
bioimaging probes was further explored by redesigning the ATSM 
ligands. By incorporating an acenaphthenequinone moiety within 
the bis(thiosemicarbazone) backbone, novel luminescent species 
were achieved and described in this work. Such aromatic metal 
complexes could potentially open a new prospective in the use of 
bis(thiosemicarbazones) as multimodal imaging tools. These 
systems can be used in vitro for optical imaging techniques 
(fluorescence microscopy) and in vivo for PET or SPECT imaging. 
The employment of a range of radionuclides such as 64Cu, 68Ga 
or 111In were also explored and the most representative examples 
presented in this review. 
 
Bis(thiosemicarbazonato) metal complexes certainly have the 
potential to catalyze the search for the ideal bifunctional chelator 
and the radiotracer design and testing research in multimodality 
imaging. Considering the interest that theranostics are currently 
generating in the scientific community, it is assured that in future 
the study of novel bis(thiosemicarbazonato) metal complexes will 
continue in order to discover new and more efficient hypoxia 
selective anti-tumor agents. 
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The aim of this review is to provide a personal account of the general background 
on the use of bis(thiosemicarbazonato) metal complexes in molecular imaging, 
which is central to the recent work in this field. We have a long-lasting interest in 
understanding the structure-function relationships underlining the potential of 
bis(thiosemicarbazonato) metal complexes for applications in multimodal imaging 
involving PET/SPECT/optical imaging modalities. The molecular design and the 
selectivity of this class of compounds for the evaluation of hypoxia is also discussed 
herein. 
